[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
June 2016

A Policy-Driven Perspective on Rising Drug Costs in Dermatology

Author Affiliations
  • 1Department of Health Policy and Management, Yale University, New Haven, Connecticut
  • 2Department of Health Policy and Management, Baylor College of Medicine, Houston, Texas
JAMA Dermatol. 2016;152(6):625-626. doi:10.1001/jamadermatol.2016.0349

In response to a growing trend of pharmaceutical price gouging, several presidential candidates have released plans1 to limit the rising cost of pharmaceuticals, some of which specifically target large pharmaceutical entities that have demonstrated a strategic preference for acquiring smaller drug companies with established therapies, as opposed to developing products internally.

First Page Preview View Large
First page PDF preview
First page PDF preview
×